<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738257</url>
  </required_header>
  <id_info>
    <org_study_id>NEO-GB-50</org_study_id>
    <secondary_id>ARE-GB-01</secondary_id>
    <nct_id>NCT00738257</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.</brief_title>
  <acronym>SMART</acronym>
  <official_title>A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH &gt; 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density
      loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A
      and glucocorticoid based immunosuppressive regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Parmidronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <arm_group_label>Parmidronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First or second kidney transplant recipients, aged 18-75 years, PTH &gt; 150 pg/ml

          2. De novo patients scheduled to receive ciclosporin A and prednisolone based
             immunosuppression.

        Exclusion Criteria:

          1. Previous or current bone disease unrelated to end stage renal failure.

          2. Patients with PTH &lt; 150pg/ml who may be at risk of adynamic bone disease.

          3. Treatment at any time with a bisphosphonate.

          4. d. Calcitonin treatment during the previous month.

          5. Malignancy (current or history within last 5 years)

          6. Pregnancy or lactation, or women of childbearing potential unwilling to use an
             effective form of contraception for the 12 month duration of the study.

        Protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Cunningham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal London Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frimley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>May 14, 2010</last_update_submitted>
  <last_update_submitted_qc>May 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>transplant,</keyword>
  <keyword>pamidronate,</keyword>
  <keyword>ciclosporin,</keyword>
  <keyword>Ciclosporin A,</keyword>
  <keyword>steroids,</keyword>
  <keyword>bone mineral density,</keyword>
  <keyword>fracture rates</keyword>
  <keyword>immunosuppressive</keyword>
  <keyword>regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

